Keyword Overview: LDL CHOLESTEROL

LDL CHOLESTEROL Overview

Upcoming Projects (LDL CHOLESTEROL)

Don’t see a project related to the keyword you care about? Create your own!

Executed Projects (LDL CHOLESTEROL)

A Third View: Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 26, 2024 at 09:30 AM EDT
A Second View: Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 12, 2024 at 10:00 AM EDT
Discussing the recent data from the Phase III V-MONO clinical trial of Leqvio in patients at risk of developing atherosclerotic cardiovascular disease
Ticker: NVS
Executed On: Sep 05, 2024 at 11:00 AM EDT
A Third Look: Investigating the Phase 3 LIBerate clinical trial of Lerodalcibep for the treatment of high cholesterol.
Ticker: LIB THERAPEUTICS
Executed On: Jul 12, 2024 at 12:00 PM EDT
A Second Look: Investigating the Phase 3 LIBerate clinical trial of Lerodalcibep for the treatment of high cholesterol.
Ticker: LIB THERAPEUTICS
Executed On: Jun 10, 2024 at 10:00 AM EDT
Investigating the Phase 3 LIBerate clinical trial of Lerodalcibep for the treatment of high cholesterol.
Ticker: LIB THERAPEUTICS
Executed On: Apr 25, 2024 at 05:30 PM EDT
A Third View: Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Apr 02, 2024 at 07:30 PM EDT
A Second View: Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Mar 29, 2024 at 10:00 AM EDT
Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Mar 28, 2024 at 03:30 PM EDT
A Third Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 22, 2023 at 05:05 PM EST
A Second Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 20, 2023 at 11:00 AM EST
Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 17, 2023 at 12:35 PM EST
A third look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Sep 07, 2023 at 06:00 PM EDT
A second look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Aug 31, 2023 at 12:30 PM EDT
A third look: Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 30, 2023 at 11:00 AM EDT
Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Aug 25, 2023 at 05:00 PM EDT
A second look: Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 25, 2023 at 03:00 PM EDT
Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.
Ticker: NVS
Executed On: Aug 24, 2023 at 07:15 PM EDT
A Third look: Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 19, 2023 at 12:00 PM EDT
A Second look: Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 15, 2023 at 05:00 PM EDT
A third look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 07:00 PM EDT
A second look: Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 14, 2023 at 06:00 PM EDT
Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 14, 2023 at 09:00 AM EDT
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker: MRK
Executed On: Mar 13, 2023 at 04:00 PM EDT
A Third View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 27, 2023 at 11:00 AM EST
A Second View: Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 09, 2023 at 03:00 PM EST
Delving into the recent data from the ROSE2 clinical trial on obicetrapid by NewAmsterdam Pharma for the treatment of Heart Disease.
Ticker: NAMS
Executed On: Feb 06, 2023 at 04:00 PM EST
A third look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 18, 2022 at 03:00 PM EST
A second look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 07, 2022 at 11:30 AM EST
A look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker: ME
Executed On: Nov 03, 2022 at 04:00 PM EDT
A Third look: Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).
Ticker: ESPR
Executed On: Oct 13, 2022 at 02:30 PM EDT
A second look: Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).
Ticker: ESPR
Executed On: Oct 06, 2022 at 02:00 PM EDT
Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).
Ticker: ESPR
Executed On: Oct 06, 2022 at 09:30 AM EDT

Upcoming & Overdue Catalysts (LDL CHOLESTEROL)

Don’t see a catalyst related to the keyword you care about? Create your own!

Strategic Initiatives (LDL CHOLESTEROL)

Don’t see a strategic initiative related to the keyword you care about? Create your own!